FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Edo Vellenga

Research Profile

Chemicals & Drugs

Anatomy

Disorders

Procedures

Physiology

Co-author Network

Publications

TOP 3
Ewout J Houwerzijl; André B Mulder; Fiona A J van den Heuvel; Johannes van der Want; Nel R Blom; Edo Vellenga
Sinusoidal endothelial cells are damaged and display enhanced autophagy in myelodysplastic syndromes.
S J Horton; Gerwin Huls; J Jaques; Maria Mesuraca; G Morrone; J van Dijk; Edo Vellenga; C Woolthuis; Jan Jacob Schuringa
MLL-AF9-mediated immortalization of human hematopoietic cells along different lineages changes during ontogeny.
Vincent van den Boom; Djoke van Gosliga; Edo Vellenga; Giuseppe Viglietto; Francesco Bonardi; Fabrizia Fusetti; Anne Margriet Heijink; Donatella Malanga; Giovanni Morrone; Marjan Rozenveld-Geugien; Jan Jacob Schuringa
Nonredundant and locus-specific gene repression functions of PRC1 paralog family members in human hematopoietic stem/progenitor cells.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Edo Vellenga (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Ewout J Houwerzijl; André B Mulder; Fiona A J van den Heuvel; Johannes van der Want; Nel R Blom; Edo Vellenga
Sinusoidal endothelial cells are damaged and display enhanced autophagy in myelodysplastic syndromes.
British journal of haematology 2013;161(3):443-6.
2013: S J Horton; Gerwin Huls; J Jaques; Maria Mesuraca; G Morrone; J van Dijk; Edo Vellenga; C Woolthuis; Jan Jacob Schuringa
MLL-AF9-mediated immortalization of human hematopoietic cells along different lineages changes during ontogeny.
Leukemia 2013;27(5):1116-26.
2013: Vincent van den Boom; Djoke van Gosliga; Edo Vellenga; Giuseppe Viglietto; Francesco Bonardi; Fabrizia Fusetti; Anne Margriet Heijink; Donatella Malanga; Giovanni Morrone; Marjan Rozenveld-Geugien; Jan Jacob Schuringa
Nonredundant and locus-specific gene repression functions of PRC1 paralog family members in human hematopoietic stem/progenitor cells.
Blood 2013;121(13):2452-61.
2013: Francesco Bonardi; Patrick Deelen; Fabrizia Fusetti; Djoke van Gosliga; Edo Vellenga; Jan Jacob Schuringa
A proteomics and transcriptomics approach to identify leukemic stem cell (LSC) markers.
Molecular & cellular proteomics : MCP 2013;12(3):626-37.
2013: Stefan Gröschel; Marije Havermans; Jürgen Krauter; Michael W M Kühn; Bob Löwenberg; Michael Lübbert; Gert J Ossenkoppele; Thomas Pabst; Veronika Rockova; Brigitte Schlegelberger; Richard F Schlenk; Ingo G H Schmidt-Wolf; Gerrit J Schuurhuis; Veronica Teleanu; Peter J M Valk; Peter Vandenberghe; Edo Vellenga; Leo F Verdonck; Gregor Verhoef; Hartmut Döhner; Konstanze Döhner; Karina Eiwen; Jan Engelmann; Claudia Erpelinck; Arnold Ganser; Ulrich Germing; Mario Bargetzi; Berna Beverloo; Ruud Delwel
Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(1):95-103.
2012: Gert J Ossenkoppele; Thomas Pabst; Jakob R Passweg; Harry C Schouten; Georg Stussi; Arjan A van de Loosdrecht; Marinus van Marwijk Kooij; Kees van Montfort; Yvette van Norden; Edo Vellenga; Gregor Verhoef; Pierre W Wijermans; Bart J Biemond; Dimitri Breems; Georgine E De Greef; Okke de Weerdt; August Ferrant; Carlos Graux; C J M Halkes; Rene M Hollestein; Mels Hoogendoorn; Mojca Jongen-Lavrencic; Mark D Levin; Johan Maertens; Bob Löwenberg
Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK).
Blood 2012;120(24):4706-11.
2012: Joost H A Martens; Sadia Saeed; Femke Simmer; Abhishek A Singh; Lucia Altucci; Amit Mandoli; Edo Vellenga; Bart-Jan Wierenga; Hendrik G Stunnenberg
ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.
Blood 2012;120(19):4038-48.
2012: Esther G M de Waal; Riemer H J A Slart; Edo Vellenga
Is FDG PET a better imaging tool than somatostatin receptor scintigraphy in patients with relapsing multiple myeloma?
Clinical nuclear medicine 2012;37(10):939-42.
2012: Pieter Sonneveld; Marian Stevens-Kroef; Bronno van der Holt; Helgi van der Velde; Marinus van Marwijk Kooy; Edo Vellenga; Katja C Weisel; Pierre W Wijermans; Shulamiet Wittebol; Sonja Zweegman; Dirk Hose; Anna Jauch; Marie-Jose Kersten; Walter Lindemann; Henk M Lokhorst; Michael Pfreundschuh; Reinier Raymakers; Hans Salwender; M Ronald Schaafsma; Christof Scheid; Ingo G H Schmidt-Wolf; Uta Bertsch; Igor W Blau; Gerard M J Bos; Annemiek Broyl; Ulrich Duehrsen; Laila El Jarari; Hartmut M Goldschmidt
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(24):2946-55.
2012: Jan J Cornelissen; Alois A Gratwohl; Berna Beverloo; Bart J Biemond; Dimitri Breems; Johan Maertens; Gert J Ossenkoppele; Thomas Pabst; Jakob R Passweg; Marinus van Marwijk Kooy; Wim L J van Putten; Edo Vellenga; Leo F Verdonck; Pierre W Wijermans; Bob Löwenberg
Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(17):2140-6.
2012: Thomas Pabst; Jakob Passweg; Harry C Schouten; Peter Sonneveld; Matthias Theobald; Wim van Putten; Marie-Christiane Vekemans; Edo Vellenga; Leo Verdonck; Mario Bargetzi; Bart Biemond; Carlos Graux; Emanuel Jacky; Marie-Cecile Legdeur; Bob Löwenberg; Johan Maertens; Gert Jan Ossenkoppele
Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine.
Blood 2012;119(23):5367-73.
2012: C M Woolthuis; L Han; Philip M Kluin; Jan Jacob Schuringa; Djoke van Gosliga; Edo Vellenga; R N Verkaik-Schakel; Gerwin Huls
Downregulation of MEIS1 impairs long-term expansion of CD34+ NPM1-mutated acute myeloid leukemia cells.
Leukemia 2012;26(4):848-53.
2012: Karen van der Weide; Susan de Jonge-Peeters; Elisabeth G E de Vries; Rudolf S N Fehrmann; Gerwin Huls; Folkert Kuipers; Jan Jacob Schuringa; Edo Vellenga
Treatment with high-dose simvastatin inhibits geranylgeranylation in AML blast cells in a subset of AML patients.
Experimental hematology 2012;40(3):177-186.e6.
2012: Hagop M Kantarjian; Dong-Wook Kim; Jorge H Milone; Franck E Nicolini; Michinori Ogura; Carolina Pavlovsky; Tadeusz Robak; Neil P Shah; María Soledad Undurraga; Jan Van Droogenbroeck; Edo Vellenga; Jianxiang Wang; Chao Zhu; Juan Julio Kassack Ipiña; Mohan B Agarwal; Michele Baccarani; M Brigid Bradley-Garelik; Jorge E Cortes; Christian Junghanss; Andreas Hochhaus
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
Blood 2012;119(5):1123-9.
2011: Reinhard Bos; Esther G M de Waal; Bouke P C Hazenberg; Hilde Kuiper; Edo Vellenga
Thalidomide and dexamethasone followed by autologous stem cell transplantation for scleromyxoedema.
Rheumatology (Oxford, England) 2011;50(10):1925-6.
2011: Eva Barragán; María J Calasanz; Mireia Camos; CM Chillón; Dolors Colomer; Óscar Fuster; Maria T Gómez-Casares; Marcos González; José González-Campos; María J Larrayoz; Javier López; Bob Lowenberg; Félix Manso; Pau Montesinos; José Román-Gómez; Pedro Sánchez-Godoy; Miguel A Sanz; Edo Vellenga; Maria L Amador; Rosa Ayala
Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy.
Haematologica 2011;96(10):1470-7.
2011: Hendrik J M de Jonge; Eveline S J M de Bont; Gert Ossenkoppele; Jan Jacob Schuringa; Peter J M Valk; Edo Vellenga; Gerwin Huls
Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD.
Haematologica 2011;96(9):1310-7.
2011: Alida C Weidenaar; Wilfred F A den Dunnen; Willem A Kamps; Gineke Koopmans-Klein; Tiny Meeuwsen-de Boer; Stefano Rosati; Arja ter Elst; Edo Vellenga; Eveline S J M de Bont
High acute myeloid leukemia derived VEGFA levels are associated with a specific vascular morphology in the leukemic bone marrow.
Cellular oncology (Dordrecht) 2011;34(4):289-96.
2011: Li-na Han; Jan Jacob Schuringa; Jin Zhou; Edo Vellenga
Treatment strategies in acute myeloid leukemia.
Chinese medical journal 2011;124(9):1409-21.
2011: Ali Agool; Riemer H J A Slart; Philip M Kluin; Joost Th M de Wolf; Rudi A J O Dierckx; Edo Vellenga
F-18 FLT PET: a noninvasive diagnostic tool for visualization of the bone marrow compartment in patients with aplastic anemia: a pilot study.
Clinical nuclear medicine 2011;36(4):286-9.
2011: Szabolcs Fatrai; Albertus T J Wierenga; S M G J Daenen; Edo Vellenga; Jan Jacob Schuringa
Identification of HIF2alpha as an important STAT5 target gene in human hematopoietic stem cells.
Blood 2011;117(12):3320-30.
2011: Bob Löwenberg; Thomas Pabst; Edo Vellenga; Wim L J van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Bart J Biemond; Alois Gratwohl; Georgine E De Greef; Leo F Verdonck; M Ronald Schaafsma; Michael Gregor; Matthias Theobald; Urs Schanz; Johan Maertens; Gert Ossenkoppele
Cytarabine dose for acute myeloid leukemia.
The New England journal of medicine 2011;364(11):1027-36.
2011: Szabolcs Fatrai; Djoke van Gosliga; Lina Han; Simon M G J Daenen; Edo Vellenga; Jan Jacob Schuringa
KRAS(G12V) enhances proliferation and initiates myelomonocytic differentiation in human stem/progenitor cells via intrinsic and extrinsic pathways.
The Journal of biological chemistry 2011;286(8):6061-70.
2011: Pau Montesinos; Chelo Rayón; Edo Vellenga; Salut Brunet; José González; Marcos González; Aleksandra Holowiecka; Jordi Esteve; Juan Bergua; José D González; Concha Rivas; Mar Tormo; Vicente Rubio; Javier Bueno; Félix Manso; Gustavo Milone; Javier de la Serna; Inmaculada Pérez; Manuel Pérez-Encinas; Isabel Krsnik; Josep M Ribera; Lourdes Escoda; Bob Lowenberg; Miguel A Sanz
Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.
Blood 2011;117(6):1799-805.
2011: Ali Agool; Riemer H J A Slart; Kristin K Thorp; Andor W J M Glaudemans; David C P Cobben; Lukas B Been; Fred R Burlage; Philip H Elsinga; Rudi A J O Dierckx; Edo Vellenga; Jennifer L Holter
Effect of radiotherapy and chemotherapy on bone marrow activity: a 18F-FLT-PET study.
Nuclear medicine communications 2011;32(1):17-22.
2011: Ali Agool; Andor W J M Glaudemans; Hendrikus H Boersma; Rudi A J O Dierckx; Edo Vellenga; Riemer H J A Slart
Radionuclide imaging of bone marrow disorders.
European journal of nuclear medicine and molecular imaging 2011;38(1):166-78.
2011: C Woolthuis; A Agool; S Olthof; R H J A Slart; G Huls; w martin smid; Jan Jacob Schuringa; Edo Vellenga
Auto-SCT induces a phenotypic shift from CMP to GMP progenitors, reduces clonogenic potential and enhances in vitro and in vivo cycling activity defined by (18)F-FLT PET scanning.
Bone marrow transplantation 2011;46(1):110-5.
2010: Martin S Tallman; Haesook T Kim; Pau Montesinos; Frederick R Appelbaum; Javier de la Serna; John M Bennett; Guillermo Deben; Clara D Bloomfield; Jose Gonzalez; James H Feusner; Marcos Gonzalez; Robert E Gallagher; Jose D Gonzalez-San Miguel; Richard A Larson; Gustavo Milone; Elisabeth Paietta; Chelo Rayon; Jacob M Rowe; Concha Rivas; Charles Alan Schiffer; Edo Vellenga; Lois Shepherd; James L Slack; Peter H Wiernik; Cheryl L Willman; Miguel A Sanz
Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group.
Blood 2010;116(25):5650-9.
2010: Aleksandra Rizo; Sarah J Horton; Sandra Olthof; Bert Dontje; Albertina Ausema; Ronald van Os; Vincent van den Boom; Edo Vellenga; Gerald de Haan; Jan Jacob Schuringa
BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells.
Blood 2010;116(22):4621-30.
2010: Annemiek Broyl; Dirk Hose; Henk M Lokhorst; Yvonne de Knegt; Justine Peeters; Anna Jauch; Uta Bertsch; Arjan Buijs; Marian Stevens-Kroef; Berna Beverloo; Edo Vellenga; Sonja Zweegman; Marie-Josée Kersten; Bronno van der Holt; Laila el Jarari; George Mulligan; Hartmut Goldschmidt; Mark van Duin; Pieter Sonneveld
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.
Blood 2010;116(14):2543-53.
2010: Lina Han; Jan Jacob Schuringa; André Mulder; Edo Vellenga
Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases.
Annals of hematology 2010;89(9):861-71.
2010: Sanne Lugthart; Stefan Gröschel; Berna Beverloo; Sabine Kayser; Peter J M Valk; Shama Lydia van Zelderen-Bhola; Gert Jan Ossenkoppele; Edo Vellenga; Eva van den Berg-de Ruiter; Urs Schanz; Gregor Verhoef; Peter Vandenberghe; Augustin Ferrant; Claus-Henning Köhne; Michael Pfreundschuh; Heinz A Horst; Elisabeth Koller; Marie von Lilienfeld-Toal; Martin Bentz; Arnold Ganser; Brigitte Schlegelberger; Martine Jotterand; Jürgen Krauter; Thomas Pabst; Matthias Theobald; Richard F Schlenk; Ruud Delwel; Konstanze Döhner; Bob Löwenberg; Hartmut Döhner
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3890-8.
2010: Ali Agool; Rudi A J O Dierckx; Joost T M de Wolf; Edo Vellenga; Riemer H J A Slart
Extramedullary haematopoiesis imaging with 18F-FLT PET.
European journal of nuclear medicine and molecular imaging 2010;37(8):1620.
2010: Gerwin Huls; André B Mulder; Stefano Rosati; Arjan A van de Loosdrecht; Edo Vellenga; Joost T M de Wolf
Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis.
Blood 2010;116(2):180-2.
2010: B Daan Westenbrink; Adriaan Voors; Rudolf A de Boer; Jan Jacob Schuringa; Theo Klinkenberg; Pim van der Harst; Edo Vellenga; Dirk J van Veldhuisen; Wiek H van Gilst
Bone marrow dysfunction in chronic heart failure patients.
European journal of heart failure 2010;12(7):676-84.
2010: Jan J Schuringa; Edo Vellenga
Role of the polycomb group gene BMI1 in normal and leukemic hematopoietic stem and progenitor cells.
Current opinion in hematology 2010;17(4):294-9.
2010: Albertus T J Wierenga; Edo Vellenga; Jan Jacob Schuringa
Down-regulation of GATA1 uncouples STAT5-induced erythroid differentiation from stem/progenitor cell proliferation.
Blood 2010;115(22):4367-76.
2010: Evelien Kneppers; Henk M Lokhorst; Corien M Eeltink; Gerwin Huls; Marie José Kersten; Jan Koedam; Monique C Minnema; Marinus H J van Oers; Reinier A P Raymakers; Martijn R Schaafsma; Edo Vellenga; Pierre W Wijermans; Shulamiet Wittebol; Pieter Sonneveld; Sonja Zweegman
Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program.
Clinical lymphoma, myeloma & leukemia 2010;10(2):138-43.
2010: Bob Löwenberg; Joachim Beck; Carlos Graux; Wim van Putten; Harry C Schouten; Leo F Verdonck; Augustin Ferrant; Pieter Sonneveld; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Dimitri Breems; Hilde de Muijnck; Ron Schaafsma; Gregor Verhoef; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gert Ossenkoppele; Johan Maertens
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study.
Blood 2010;115(13):2586-91.
2010: Ingrid I van Gameren; Bouke P C Hazenberg; Johan Bijzet; Elizabeth B Haagsma; Edo Vellenga; Marcel D Posthumus; Pieter L Jager; Martin H van Rijswijk
Amyloid load in fat tissue reflects disease severity and predicts survival in amyloidosis.
Arthritis care & research 2010;62(3):296-301.
2010: José Cervera; Pau Montesinos; Jesús M Hernández-Rivas; María J Calasanz; Anna Aventín; María T Ferro; Elisa Luño; Javier Sánchez; Edo Vellenga; Chelo Rayón; Gustavo Milone; Javier de la Serna; Concha Rivas; José D González; Mar Tormo; Elena Amutio; Marcos González; Salut Brunet; Bob Lowenberg; Miguel A Sanz
Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
Haematologica 2010;95(3):424-31.
2010: Henk M Lokhorst; Bronno van der Holt; Sonja Zweegman; Edo Vellenga; Sandra Croockewit; Marinus H J van Oers; Peter von dem Borne; Pierre W Wijermans; Ron Schaafsma; Okke de Weerdt; Shulamiet Wittebol; Michel Delforge; Henriëtte Berenschot; Gerard M Bos; Kon-Siong G Jie; Harm Sinnige; Marinus van Marwijk Kooy; Peter Joosten; Monique C Minnema; Rianne van Ammerlaan; Pieter Sonneveld
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.
Blood 2010;115(6):1113-20.
2010: Michael Schaapveld; Otto Visser; Sabine Siesling; Cees G Schaar; Sonja Zweegman; Edo Vellenga
Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989.
European journal of cancer (Oxford, England : 1990) 2010;46(1):160-9.
2010: Ali Agool; Riemer H J A Slart; Rudi A J O Dierckx; Philip M Kluin; Lydia Visser; Pieter L Jager; Edo Vellenga
Somatostatin receptor scintigraphy might be useful for detecting skeleton abnormalities in patients with multiple myeloma and plasmacytoma.
European journal of nuclear medicine and molecular imaging 2010;37(1):124-30.
2009: Christian R Geest; Miranda Buitenhuis; Marian J A Groot Koerkamp; Frank C P Holstege; Edo Vellenga; Paul J Coffer
Tight control of MEK-ERK activation is essential in regulating proliferation, survival, and cytokine production of CD34+-derived neutrophil progenitors.
Blood 2009;114(16):3402-12.
2009: Hendrik J M de Jonge; Eveline S J M de Bont; Peter J M Valk; Jan Jacob Schuringa; Marcel Kies; Carolien M Woolthuis; Ruud Delwel; Nic J G M Veeger; Edo Vellenga; Bob Löwenberg; Gerwin Huls
AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance.
Blood 2009;114(14):2869-77.
2009: Bob Löwenberg; Gert Ossenkoppele; Wim L J van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Johan Maertens; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Marinus van Marwijk Kooy; Leo F Verdonck; Joachim Beck; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gregor Verhoef
High-dose daunorubicin in older patients with acute myeloid leukemia.
The New England journal of medicine 2009;361(13):1235-48.
2009: Christian R Geest; Miranda Buitenhuis; Annemieke G Laarhoven; Marc Bierings; Marrie C A Bruin; Edo Vellenga; Paul J Coffer
p38 MAP kinase inhibits neutrophil development through phosphorylation of C/EBPalpha on serine 21.
Stem cells (Dayton, Ohio) 2009;27(9):2271-82.
2009: Gwenny M Fuhler; Monika R Tyl; Sandra G M Olthof; A Lyndsay Drayer; Nel R Blom; Edo Vellenga
Distinct roles of the mTOR components Rictor and Raptor in MO7e megakaryocytic cells.
European journal of haematology 2009;83(3):235-45.
2009: Aleksandra Rizo; Sandra Olthof; Lina Han; Edo Vellenga; Gerald de Haan; Jan Jacob Schuringa
Repression of BMI1 in normal and leukemic human CD34(+) cells impairs self-renewal and induces apoptosis.
Blood 2009;114(8):1498-505.
2009: Arjan Diepstra; Gustaaf W van Imhoff; Michael Schaapveld; Henrike Karim-Kos; Anke Van den Berg; Edo Vellenga; Sibrand Poppema
Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(23):3815-21.
2009: Ingrid I van Gameren; Martin H van Rijswijk; Johan Bijzet; Edo Vellenga; Bouke P C Hazenberg
Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain.
Haematologica 2009;94(8):1094-100.
2009: Christian R Geest; Miranda Buitenhuis; Edo Vellenga; Paul J Coffer
Ectopic expression of C/EBPalpha and ID1 is sufficient to restore defective neutrophil development in low-risk myelodysplasia.
Haematologica 2009;94(8):1075-84.
2009: Christian R Geest; Fried J Zwartkruis; Edo Vellenga; Paul J Coffer; Miranda Buitenhuis
Mammalian target of rapamycin activity is required for expansion of CD34+ hematopoietic progenitor cells.
Haematologica 2009;94(7):901-10.
2009: Susan D P W M de Jonge-Peeters; Karen van der Weide; Folkert Kuipers; Wim J Sluiter; Elisabeth G E de Vries; Edo Vellenga
Variability in responsiveness to lovastatin of the primitive CD34+ AML subfraction compared to normal CD34+ cells.
Annals of hematology 2009;88(6):573-80.
2009: Karen van der Weide; Susan D P W M de Jonge-Peeters; Folkert Kuipers; Elisabeth G E de Vries; Edo Vellenga
Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(9):3076-83.
2009: Ewout J Houwerzijl; H-W D Pol; Nel R Blom; Johannes van der Want; J Th M de Wolf; Edo Vellenga
Erythroid precursors from patients with low-risk myelodysplasia demonstrate ultrastructural features of enhanced autophagy of mitochondria.
Leukemia 2009;23(5):886-91.
2009: Yvonne H Tromp; S M G J Daenen; Wim J Sluiter; Edo Vellenga
The predictive value of interleukin-8 (IL-8) in hospitalised patients with fever and chemotherapy-induced neutropenia.
European journal of cancer (Oxford, England : 1990) 2009;45(4):596-600.
2009: Pau Montesinos; Juan M Bergua; Edo Vellenga; Chelo Rayón; Ricardo Parody; Javier de la Serna; Angel León; Jordi Esteve; Gustavo Milone; Guillermo Deben; Concepción Rivas; Marcos González; Mar Tormo; Joaquín Díaz-Mediavilla; José D González; Silvia Negri; Elena Amutio; Salut Brunet; Bob Lowenberg; Miguel A Sanz
Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors.
Blood 2009;113(4):775-83.
2009: Lina Han; Albertus T J Wierenga; Marjan Rozenveld-Geugien; Kim van de Lande; Edo Vellenga; Jan Jacob Schuringa
Single-cell STAT5 signal transduction profiling in normal and leukemic stem and progenitor cell populations reveals highly distinct cytokine responses.
PloS one 2009;4(11):e7989.
2008: Ewout J Houwerzijl; Henk Louwes; Wim J Sluiter; Jan W Smit; Edo Vellenga; J Th M de Wolf
Platelet production rate predicts the response to prednisone therapy in patients with idiopathic thrombocytopenic purpura.
Annals of hematology 2008;87(12):975-83.
2008: Albertus T J Wierenga; Edo Vellenga; Jan Jacob Schuringa
Maximal STAT5-induced proliferation and self-renewal at intermediate STAT5 activity levels.
Molecular and cellular biology 2008;28(21):6668-80.
2008: Miguel A Sanz; Pau Montesinos; Edo Vellenga; Chelo Rayón; Javier de la Serna; Ricardo Parody; Juan M Bergua; Angel León; Silvia Negri; Marcos González; Concepción Rivas; Jordi Esteve; Gustavo Milone; José D González; Elena Amutio; Salut Brunet; J García-Laraña; Dolors Colomer; María J Calasanz; Carmen Chillón; Eva Barragán; Pascual Bolufer; Bob Lowenberg
Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group.
Blood 2008;112(8):3130-4.
2008: Szabolcs Fatrai; Hein Schepers; Henko Tadema; Edo Vellenga; S M G J Daenen; Jan Jacob Schuringa
Mucin1 expression is enriched in the human stem cell fraction of cord blood and is upregulated in majority of the AML cases.
Experimental hematology 2008;36(10):1254-65.
2008: Sandra G M Olthof; Szabolcs Fatrai; A Lyndsay Drayer; Monika R Tyl; Edo Vellenga; Jan Jacob Schuringa
Downregulation of signal transducer and activator of transcription 5 (STAT5) in CD34+ cells promotes megakaryocytic development, whereas activation of STAT5 drives erythropoiesis.
Stem cells (Dayton, Ohio) 2008;26(7):1732-42.
2008: Javier de la Serna; Pau Montesinos; Edo Vellenga; Chelo Rayón; Ricardo Parody; Angel León; Jordi Esteve; Juan M Bergua; Gustavo Milone; Guillermo Deben; Concepción Rivas; Marcos González; Mar Tormo; Joaquín Díaz-Mediavilla; Jose D González; Silvia Negri; Elena Amutio; Salut Brunet; Bob Lowenberg; Miguel A Sanz
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.
Blood 2008;111(7):3395-402.
2008: Janine K Kruit; A Lyndsay Drayer; Vincent Bloks; Nel R Blom; Sandra G Olthof; Pieter J J Sauer; Gerald de Haan; Ido P Kema; Edo Vellenga; Folkert Kuipers
Plant sterols cause macrothrombocytopenia in a mouse model of sitosterolemia.
The Journal of biological chemistry 2008;283(10):6281-7.
2008: Aleksandra Rizo; Bert Dontje; Edo Vellenga; Gerald de Haan; Jan Jacob Schuringa
Long-term maintenance of human hematopoietic stem/progenitor cells by expression of BMI1.
Blood 2008;111(5):2621-30.
2008: Lionel Adès; Miguel A Sanz; Sylvie Chevret; Pau Montesinos; Patrice Chevallier; Emmanuel Raffoux; Edo Vellenga; Agnès Guerci; Arnaud Pigneux; Francoise Huguet; C Rayon; Anne-Marie Stoppa; Javier de la Serna; Jean-Yves Cahn; Sandrine Meyer-Monard; Thomas Pabst; Xavier Thomas; Stéphane de Botton; Ricardo Parody; Juan Bergua; Thierry Lamy; Anne Vekhoff; Silvia Negri; Norbert Ifrah; Hervé Dombret; Augustin Ferrant; Dominique Bron; Laurent Degos; Pierre Fenaux
Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results.
Blood 2008;111(3):1078-84.
2008: Edo Vellenga; Wim L J van Putten; Mars B van 't Veer; Josée M Zijlstra; Willem E Fibbe; Marinus H J van Oers; Leo F Verdonck; Pierre W Wijermans; Gustaaf W van Imhoff; Pieternella J Lugtenburg; Peter C Huijgens
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial.
Blood 2008;111(2):537-43.
2008: Henk M Lokhorst; Ingo Schmidt-Wolf; Pieter Sonneveld; Bronno van der Holt; Hans Martin; Renée M Y Barge; Uta Bertsch; Jana Schlenzka; Gerard M J Bos; Sandra Croockewit; Sonja Zweegman; Iris Breitkreutz; Iris Breitkreuz; Peter Joosten; Christof Scheid; Marinus van Marwijk Kooy; Hans Salwender; Marinus H J van Oers; Ron Schaafsma; Ralph Naumann; Harm Sinnige; Igor Blau; Michel Delforge; Gregor Verhoef; Okke de Weerdt; Pierre W Wijermans; Shulamiet Wittebol; Ulrich Duersen; Edo Vellenga; Hartmut Goldschmidt
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.
Haematologica 2008;93(1):124-7.
2008: Gwenny M Fuhler; A Lyndsay Drayer; Sandra G M Olthof; Jan Jacob Schuringa; Paul J Coffer; Edo Vellenga
Reduced activation of protein kinase B, Rac, and F-actin polymerization contributes to an impairment of stromal cell derived factor-1 induced migration of CD34+ cells from patients with myelodysplasia.
Blood 2008;111(1):359-68.
2008: Irene H Heijink; Henk Kauffman; Edo Vellenga; Christa A Veltman-Starkenburg; Dirkje S Postma; Jan G R de Monchy
Effect of ciclesonide treatment on allergen-induced changes in T cell regulation in asthma.
International archives of allergy and immunology 2008;145(2):111-21.
2007: Hein Schepers; Djoke van Gosliga; Albertus T J Wierenga; Bart Eggen; Jan Jacob Schuringa; Edo Vellenga
STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells.
Blood 2007;110(8):2880-8.
2007: Djoke van Gosliga; Hein Schepers; Aleksandra Rizo; Dorina M van der Kolk; Edo Vellenga; Jan Jacob Schuringa
Establishing long-term cultures with self-renewing acute myeloid leukemia stem/progenitor cells.
Experimental hematology 2007;35(10):1538-49.
2007: Hein Schepers; Albertus T J Wierenga; Djoke van Gosliga; Bart Eggen; Edo Vellenga; Jan Jacob Schuringa
Reintroduction of C/EBPalpha in leukemic CD34+ stem/progenitor cells impairs self-renewal and partially restores myelopoiesis.
Blood 2007;110(4):1317-25.
2007: Arjan Diepstra; Gustaaf W van Imhoff; Henrike E Karim-Kos; Anke Van den Berg; Gerard te Meerman; Marijke Niens; Ilja M Nolte; Esther Bastiaannet; Michael Schaapveld; Edo Vellenga; Sibrand Poppema
HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(21):3101-8.
2007: Pieter Sonneveld; Bronno van der Holt; Christine M Segeren; Edo Vellenga; Alexandra J Croockewit; Gregor E G Verhoe; Jan J Cornelissen; M Ronald Schaafsma; Marinus H J van Oers; Pierre W Wijermans; Petra H M Westveer; Henk M Lokhorst
Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial.
Haematologica 2007;92(7):928-35.
2007: S M G J Daenen; Gustaaf W van Imhoff; J Th M de Wolf; Edo Vellenga; Eva van den Berg-de Ruiter; Hanneke C Kluin-Nelemans
A 'pre-induction course' with non-cross-reacting cytostatic drugs for rapid tumour load reduction improves outcome in adult acute lymphoblastic leukaemia.
British journal of haematology 2007;138(2):275-7.
2007: Irene H Heijink; P Marcel Kies; Henk Kauffman; Dirkje S Postma; Antoon J M Van Oosterhout; Edo Vellenga
Down-regulation of E-cadherin in human bronchial epithelial cells leads to epidermal growth factor receptor-dependent Th2 cell-promoting activity.
Journal of immunology (Baltimore, Md. : 1950) 2007;178(12):7678-85.
2007: Bouke P C Hazenberg; Martin H van Rijswijk; Marjolijn N Lub-de Hooge; Edo Vellenga; Elizabeth B Haagsma; Marcel D Posthumus; Pieter L Jager
Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2007;48(6):865-72.
2007: Susan D P W M de Jonge-Peeters; Folkert Kuipers; Elisabeth G E de Vries; Edo Vellenga
ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance.
Critical reviews in oncology/hematology 2007;62(3):214-26.
2007: Marjan Rozenveld-Geugien; Inge O Baas; Djoke van Gosliga; Edo Vellenga; Jan Jacob Schuringa
Expansion of normal and leukemic human hematopoietic stem/progenitor cells requires rac-mediated interaction with stromal cells.
Experimental hematology 2007;35(5):782-92.
2007: Marry M van den Heuvel-Eibrink; Bronno van der Holt; Alan K Burnett; Wolfgang Knauf; Martin F Fey; Gregor Verhoef; Edo Vellenga; Gert Ossenkoppele; Bob Löwenberg; Pieter Sonneveld
CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age.
Annals of hematology 2007;86(5):329-37.
2007: Irene H Heijink; P Marcel Kies; Antoon J M Van Oosterhout; Dirkje S Postma; Henk Kauffman; Edo Vellenga
Der p, IL-4, and TGF-beta cooperatively induce EGFR-dependent TARC expression in airway epithelium.
American journal of respiratory cell and molecular biology 2007;36(3):351-9.
2007: Gwenny M Fuhler; Nel R Blom; Paul J Coffer; A Lyndsay Drayer; Edo Vellenga
The reduced GM-CSF priming of ROS production in granulocytes from patients with myelodysplasia is associated with an impaired lipid raft formation.
Journal of leukocyte biology 2007;81(2):449-57.
2007: Bart W Schot; Josée M Zijlstra; Wim J Sluiter; Gustaaf W van Imhoff; Jan Pruim; Willem Vaalburg; Edo Vellenga
Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma.
Blood 2007;109(2):486-91.
2007: Erica H Gerkes; Mirjam M de Jong; Rolf Sijmons; Edo Vellenga
Familial multiple myeloma: report on two families and discussion of screening options.
Hereditary cancer in clinical practice 2007;5(2):72-8.
2006: Hein Schepers; Bart Eggen; Jan Jacob Schuringa; Edo Vellenga
Constitutive activation of NF-kappa B is not sufficient to disturb normal steady-state hematopoiesis.
Haematologica 2006;91(12):1710-1.
2006: Ewout J Houwerzijl; Nel R Blom; Johannes van der Want; Edo Vellenga; J Th M de Wolf
Megakaryocytic dysfunction in myelodysplastic syndromes and idiopathic thrombocytopenic purpura is in part due to different forms of cell death.
Leukemia 2006;20(11):1937-42.
2006: Aleksandra Rizo; Edo Vellenga; Gerald de Haan; Jan Jacob Schuringa
Signaling pathways in self-renewing hematopoietic and leukemic stem cells: do all stem cells need a niche?
Human molecular genetics 2006;15 Spec No 2():R210-9.
2006: Ali Agool; Bart W Schot; Pieter L Jager; Edo Vellenga
18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(10):1592-8.
2006: Monique A Stokman; C S M Oude Nijhuis; F K L Spijkervet; Eveline S J M de Bont; PU Dijkstra; S M G J Daenen; Jourik A Gietema; Winette T A van der Graaf; Harry J M Groen; Edo Vellenga; Willem A Kamps
The role of oral mucositis on the systemic inflammation parameter IL-8 in febrile neutropenic cancer patients.
Cancer investigation 2006;24(5):479-83.
2006: Joyce S G Yeoh; Ronald van Os; Ellen Weersing; Albertina Ausema; Bert Dontje; Edo Vellenga; Gerald de Haan
Fibroblast growth factor-1 and -2 preserve long-term repopulating ability of hematopoietic stem cells in serum-free cultures.
Stem cells (Dayton, Ohio) 2006;24(6):1564-72.
2006: Albertus T J Wierenga; Hein Schepers; Malcolm A S Moore; Edo Vellenga; Jan Jacob Schuringa
STAT5-induced self-renewal and impaired myelopoiesis of human hematopoietic stem/progenitor cells involves down-modulation of C/EBPalpha.
Blood 2006;107(11):4326-33.
2006: Susan D P W M Peeters; Dorina M van der Kolk; Gerald de Haan; Leonid V Bystrykh; Folkert Kuipers; Elisabeth G E de Vries; Edo Vellenga
Selective expression of cholesterol metabolism genes in normal CD34+CD38- cells with a heterogeneous expression pattern in AML cells.
Experimental hematology 2006;34(5):622-30.
2006: Bouke P C Hazenberg; Martin H van Rijswijk; D Albertus Piers; Marjolijn N Lub-de Hooge; Edo Vellenga; Elizabeth B Haagsma; Philip N Hawkins; Pieter L Jager
Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis.
The American journal of medicine 2006;119(4):355.e15-24.
2006: Bart W Schot; Jan Pruim; Gustaaf W van Imhoff; Wim J Sluiter; Willem Vaalburg; Edo Vellenga
The role of serial pre-transplantation positron emission tomography in predicting progressive disease in relapsed lymphoma.
Haematologica 2006;91(4):490-5.
2006: Ronald van Os; Albertina Ausema; Estelle Noach; Kyrjon van Pelt; Bert Dontje; Edo Vellenga; Gerald de Haan
Identification of quantitative trait loci regulating haematopoietic parameters in B6AKRF2 mice.
British journal of haematology 2006;132(1):80-90.
2006: A Lyndsay Drayer; Sandra G M Olthof; Edo Vellenga
Mammalian target of rapamycin is required for thrombopoietin-induced proliferation of megakaryocyte progenitors.
Stem cells (Dayton, Ohio) 2006;24(1):105-14.
2005: Sabine L A Plasschaert; Eveline S J M de Bont; Marike Boezen; Dorina M vander Kolk; S M G J Daenen; Klaas Nico Faber; Willem A Kamps; Elisabeth G E de Vries; Edo Vellenga
Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(24 Pt 1):8661-8.
2005: C S M Oude Nijhuis; Willem A Kamps; S M G J Daenen; Jourik A Gietema; Winette T A van der Graaf; Harry J M Groen; Edo Vellenga; Els M Ten Vergert; Karin M Vermeulen; Hillie G de Vries-Hospers; Eveline S J M de Bont
Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(30):7437-44.
2005: Bronno van der Holt; Bob Löwenberg; Alan K Burnett; Wolfgang Knauf; John Shepherd; Pier Paolo Piccaluga; Gert Ossenkoppele; Gregor Verhoef; Augustin Ferrant; Michael Crump; Dominik Selleslag; Matthias Theobald; Martin F Fey; Edo Vellenga; Margaret Dugan; Pieter Sonneveld
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.
Blood 2005;106(8):2646-54.
2005: peter van der meer; Erik Lipsic; B Daan Westenbrink; Ruud M A van de Wal; Regien G Schoemaker; Edo Vellenga; Dirk J van Veldhuisen; Adriaan A Voors; Wiek H van Gilst
Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure.
Circulation 2005;112(12):1743-7.
2005: Germaine F J D Benus; Albertus T J Wierenga; David de Gorter; Jan Jacob Schuringa; Ariëtte M van Bennekum; Loes J Drenth-Diephuis; Edo Vellenga; Bart Eggen
Inhibition of the transforming growth factor beta (TGFbeta) pathway by interleukin-1beta is mediated through TGFbeta-activated kinase 1 phosphorylation of SMAD3.
Molecular biology of the cell 2005;16(8):3501-10.
2005: Ka Lung Wu; Wessel van Wieringen; Edo Vellenga; Sonja Zweegman; Henk M Lokhorst; Pieter Sonneveld
Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice.
Haematologica 2005;90(7):996-7.
2005: Hein Schepers; Albertus T J Wierenga; Bart Eggen; Edo Vellenga
Oncogenic Ras blocks transforming growth factor-beta-induced cell-cycle arrest by degradation of p27 through a MEK/Erk/SKP2-dependent pathway.
Experimental hematology 2005;33(7):747-57.
2005: Irene H Heijink; Edo Vellenga; Jaap Oostendorp; Jan G R de Monchy; Dirkje S Postma; Henk Kauffman
Exposure to TARC alters beta2-adrenergic receptor signaling in human peripheral blood T lymphocytes.
American journal of physiology. Lung cellular and molecular physiology 2005;289(1):L53-9.
2005: Arjan Diepstra; Marijke Niens; Edo Vellenga; Gustaaf W van Imhoff; Ilja M Nolte; Michael Schaapveld; Gerrit van der Steege; Anke Van den Berg; R E Kibbelaar; Gerard te Meerman; Sibrand Poppema
Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma.
Lancet 2005;365(9478):2216-24.
2005: Hein Schepers; Marjan Geugien; Marco van der Toorn; Anton L Bryantsev; Harm H Kampinga; Bart Eggen; Edo Vellenga
HSP27 protects AML cells against VP-16-induced apoptosis through modulation of p38 and c-Jun.
Experimental hematology 2005;33(6):660-70.
2005: Ewout J Houwerzijl; Henk Louwes; Mariet T Esselink; Jan W Smit; Edo Vellenga; J Th M de Wolf
Increased glycocalicin index and normal thrombopoietin levels in patients with idiopathic thrombocytopenic purpura with a decreased rate of platelet production.
Haematologica 2005;90(5):710-1.
2005: Sjoerd Hovenga; S M G J Daenen; J Th M de Wolf; Gustaaf W van Imhoff; Hanneke C Kluin-Nelemans; Wim J Sluiter; Edo Vellenga
Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study.
Annals of hematology 2005;84(5):311-6.
2005: Ewout J Houwerzijl; Nel R Blom; Johannes van der Want; Henk Louwes; Mariet T Esselink; Jan W Smit; Edo Vellenga; J Th M de Wolf
Increased peripheral platelet destruction and caspase-3-independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients.
Blood 2005;105(9):3472-9.
2005: Dimitri A Breems; Wim L J van Putten; Peter C Huijgens; Gert Ossenkoppele; Gregor Verhoef; Leo F Verdonck; Edo Vellenga; Georgine E De Greef; Emanuel Jacky; Johannes Van Der Lelie; Marc Boogaerts; Bob Löwenberg
Prognostic index for adult patients with acute myeloid leukemia in first relapse.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(9):1969-78.
2005: Leonid V Bystrykh; Ellen Weersing; Bert Dontje; Sue Sutton; Mathew Pletcher; Timothy Wiltshire; Andrew Su; Edo Vellenga; Jintao Wang; Kenneth F Manly; Lu Lu; Elissa J Chesler; Rudi Alberts; Ritsert C Jansen; Robert Williams; Michael P Cooke; Gerald de Haan
Uncovering regulatory pathways that affect hematopoietic stem cell function using 'genetical genomics'.
Nature genetics 2005;37(3):225-32.
2005: Kyrjon van Pelt; Gerald de Haan; Edo Vellenga; S M G J Daenen
Administration of low-dose cytarabine results in immediate S-phase arrest and subsequent activation of cell cycling in murine stem cells.
Experimental hematology 2005;33(2):226-31.
2005: A Lyndsay Drayer; Arjen-Kars Boer; E Leonie Los; Mariet T Esselink; Edo Vellenga
Stem cell factor synergistically enhances thrombopoietin-induced STAT5 signaling in megakaryocyte progenitors through JAK2 and Src kinase.
Stem cells (Dayton, Ohio) 2005;23(2):240-51.
2005: Gwenny M Fuhler; Gerlinde J Knol; A Lyndsay Drayer; Edo Vellenga
Impaired interleukin-8- and GROalpha-induced phosphorylation of extracellular signal-regulated kinase result in decreased migration of neutrophils from patients with myelodysplasia.
Journal of leukocyte biology 2005;77(2):257-66.
2005: S D P W M Peeters; Sjoerd Hovenga; S Rosati; Edo Vellenga
Bcl-xl expression in multiple myeloma.
Medical oncology (Northwood, London, England) 2005;22(2):183-90.
2005: Georgine E De Greef; Wim L J van Putten; Marc Boogaerts; Peter C Huijgens; Leo F Verdonck; Edo Vellenga; Matthias Theobald; Emanuel Jacky; Bob Löwenberg
Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies.
British journal of haematology 2005;128(2):184-91.
2005: Leonie Marjan Kamminga; Ronald van Os; Albertina Ausema; Estelle Noach; Ellen Weersing; Bert Dontje; Edo Vellenga; Gerald de Haan
Impaired hematopoietic stem cell functioning after serial transplantation and during normal aging.
Stem cells (Dayton, Ohio) 2005;23(1):82-92.
2005: Dimitri A Breems; Marc Boogaerts; Adriaan W Dekker; Wim L J van Putten; Pieter Sonneveld; Peter C Huijgens; Johannes Van Der Lelie; Edo Vellenga; Alois Gratwohl; Gregor Verhoef; Leo F Verdonck; Bob Löwenberg
Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial.
British journal of haematology 2005;128(1):59-65.
2004: Miguel A Sanz; Edo Vellenga; Chelo Rayón; Joaquín Díaz-Mediavilla; Concepción Rivas; Elena Amutio; Jesús Arias; Guillermo Deben; Andrés Novo; Juan Bergua; Javier de la Serna; Javier Bueno; Silvia Negri; José M Beltrán de Heredia; Guillermo Martín
All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia.
Blood 2004;104(12):3490-3.
2004: Sabine L A Plasschaert; Ellis Groninger; Marike Boezen; Ido Kema; Elisabeth G E de Vries; D R A Uges; Anjo J P Veerman; Willem A Kamps; Edo Vellenga; Siebold S N de Graaf; Eveline S J M de Bont
Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia.
Clinical pharmacology and therapeutics 2004;76(3):220-9.
2004: Irene H Heijink; Maarten van den Berge; Edo Vellenga; Jan G R de Monchy; Dirkje S Postma; Henk Kauffman
Altered beta2-adrenergic regulation of T cell activity after allergen challenge in asthma.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2004;34(9):1356-63.
2004: E G E de Vries; Edo Vellenga; J C Kluin-Nelemans; Nanno H Mulder
The happy destiny of frozen haematopoietic stem cells: from immature stem cells to mature applications.
European journal of cancer (Oxford, England : 1990) 2004;40(13):1987-92.
2004: S J L Brada; AA Van De Loosdrecht; J Koudstaal; J Th M de Wolf; Edo Vellenga
Limited numbers of apoptotic cells in fresh paraffin embedded bone marrow samples of patients with myelodysplastic syndrome.
Leukemia research 2004;28(9):921-5.
2004: Gwenny M Fuhler; Karen A Cadwallader; Gerlinde J Knol; Edwin R Chilvers; A Lyndsay Drayer; Edo Vellenga
Disturbed granulocyte macrophage-colony stimulating factor priming of phosphatidylinositol 3,4,5-trisphosphate accumulation and Rac activation in fMLP-stimulated neutrophils from patients with myelodysplasia.
Journal of leukocyte biology 2004;76(1):254-62.
2004: Diana C J Spierings; Elisabeth G E de Vries; Alja J Stel; Nelina te Rietstap; Edo Vellenga; Steven de Jong
Low p21Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis.
Oncogene 2004;23(28):4862-72.
2004: Diana C J Spierings; Elisabeth G de Vries; Edo Vellenga; Fiona A J van den Heuvel; Jan J Koornstra; Jelle Wesseling; Harry Hollema; Steven de Jong
Tissue distribution of the death ligand TRAIL and its receptors.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2004;52(6):821-31.
2004: Jeroen Guikema; Sjoerd Hovenga; Edo Vellenga; Nicolaas A Bos
Heterogeneity in the multiple myeloma tumor clone.
Leukemia & lymphoma 2004;45(5):857-71.
2004: G Klein; Edo Vellenga; M W Fraaije; Willem A Kamps; Eveline S J M de Bont
The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia.
Critical reviews in oncology/hematology 2004;50(2):87-100.
2004: P Nieboer; E G E de Vries; Edo Vellenga; Winette T A van der Graaf; Nanno H Mulder; Wim J Sluiter; J Th M de Wolf
Factors influencing haematological recovery following high-dose chemotherapy and peripheral stem-cell transplantation for haematological malignancies; 1-year analysis.
European journal of cancer (Oxford, England : 1990) 2004;40(8):1199-207.
2004: Ingrid I van Gameren; Henk M Lokhorst; Bouke P C Hazenberg; Edo Vellenga
Therapeutic options in systemic AL amyloidosis.
The Netherlands journal of medicine 2004;62(4):106-13.
2004: Sabine L A Plasschaert; Dorina M van der Kolk; Eveline S J M de Bont; Edo Vellenga; Willem A Kamps; Elisabeth G E de Vries
Breast cancer resistance protein (BCRP) in acute leukemia.
Leukemia & lymphoma 2004;45(4):649-54.
2004: Sabine L A Plasschaert; Willem A Kamps; Edo Vellenga; Elisabeth G E de Vries; Eveline S J M de Bont
Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation?
Cancer treatment reviews 2004;30(1):37-51.
2004: Jeroen Guikema; Edo Vellenga; Wayel Habib Abdulahad; Sjoerd Hovenga; Nicolaas A Bos
CD27-triggering on primary plasma cell leukaemia cells has anti-apoptotic effects involving mitogen activated protein kinases.
British journal of haematology 2004;124(3):299-308.
2004: Ewout J Houwerzijl; Nel R Blom; Johannes van der Want; Mariet T Esselink; Jan J Koornstra; Jan W Smit; Henk Louwes; Edo Vellenga; J Th M de Wolf
Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura.
Blood 2004;103(2):500-6.
2004: KU Birkenkamp; Marjan Geugien; Hein Schepers; Jantine L Westra; HH Lemmink; Edo Vellenga
Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway.
Leukemia 2004;18(1):103-12.
2003: C S M Oude Nijhuis; Edo Vellenga; S M G J Daenen; Winette T A van der Graaf; Jourik A Gietema; Harry J M Groen; Willem A Kamps; Eveline S J M de Bont
Lipopolysaccharide-binding protein: a possible diagnostic marker for Gram-negative bacteremia in neutropenic cancer patients.
Intensive care medicine 2003;29(12):2157-61.
2003: Arjen-Kars Boer; A Lyndsay Drayer; Edo Vellenga
cAMP/PKA-mediated regulation of erythropoiesis.
Leukemia & lymphoma 2003;44(11):1893-901.
2003: Sabine L A Plasschaert; Dorina M van der Kolk; Eveline S J M de Bont; Willem A Kamps; Kuniaki Morisaki; Susan E Bates; George L Scheffer; Rik J Scheper; Edo Vellenga; Elisabeth G E de Vries
The role of breast cancer resistance protein in acute lymphoblastic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(14):5171-7.
2003: C S M Oude Nijhuis; Jourik A Gietema; Edo Vellenga; S M G J Daenen; Eveline S J M de Bont; Willem A Kamps; Harry J M Groen; Eric J van der Jagt; Winette T A van der Graaf
Routine radiography does not have a role in the diagnostic evaluation of ambulatory adult febrile neutropenic cancer patients.
European journal of cancer (Oxford, England : 1990) 2003;39(17):2495-8.
2003: Hein Schepers; Marjan Geugien; Bart Eggen; Edo Vellenga
Constitutive cytoplasmic localization of p21(Waf1/Cip1) affects the apoptotic process in monocytic leukaemia.
Leukemia 2003;17(11):2113-21.
2003: Bart W Schot; Gustaaf W van Imhoff; Jan Pruim; Wim Sluiter; Willem Vaalburg; Edo Vellenga
Predictive value of early 18F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma.
British journal of haematology 2003;123(2):282-7.
2003: WJ van Everdink; Ancha Baranova; C Lummen; Tatiana Tyazhelova; M W G Looman; Dmitry Ivanov; Edwin Verlind; Anna Pestova; Hette Faber; Anneke Y van der Veen; Nick Yankovsky; Edo Vellenga; Charles H C M Buys
RFP2, c13ORF1, and FAM10A4 are the most likely tumor suppressor gene candidates for B-cell chronic lymphocytic leukemia.
Cancer genetics and cytogenetics 2003;146(1):48-57.
2003: Gwenny M Fuhler; Floris Hooijenga; A Lyndsay Drayer; Edo Vellenga
Reduced expression of flavocytochrome b558, a component of the NADPH oxidase complex, in neutrophils from patients with myelodysplasia.
Experimental hematology 2003;31(9):752-9.
2003: Irene H Heijink; Henk Kauffman; Dirkje S Postma; Jan G R de Monchy; Edo Vellenga
Sensitivity of IL-5 production to the cAMP-dependent pathway in human T cells is reduced by exogenous IL-2 in a phosphoinositide 3-kinase-dependent way.
European journal of immunology 2003;33(8):2206-15.
2003: C S M Oude Nijhuis; Edo Vellenga; S M G J Daenen; Willem A Kamps; Eveline S J M de Bont
Endothelial cells are main producers of interleukin 8 through Toll-like receptor 2 and 4 signaling during bacterial infection in leukopenic cancer patients.
Clinical and diagnostic laboratory immunology 2003;10(4):558-63.
2003: Diana C J Spierings; E G E de Vries; Edo Vellenga; Steven de Jong
Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell line.
Cell death and differentiation 2003;10(7):808-22.
2003: Estelle Noach; Albertina Ausema; Ronald van Os; Imre Akkerman; Sonja Koopal; Ellen Weersing; Bert Dontje; Edo Vellenga; Gerald de Haan
Chemotherapy prior to autologous bone marrow transplantation impairs long-term engraftment in mice.
Experimental hematology 2003;31(6):528-34.
2003: Arjen-Kars Boer; A Lyndsay Drayer; Edo Vellenga
Stem cell factor enhances erythropoietin-mediated transactivation of signal transducer and activator of transcription 5 (STAT5) via the PKA/CREB pathway.
Experimental hematology 2003;31(6):512-20.
2003: Diana C J Spierings; Elisabeth G E de Vries; Edo Vellenga; Steven de Jong
The attractive Achilles heel of germ cell tumours: an inherent sensitivity to apoptosis-inducing stimuli.
The Journal of pathology 2003;200(2):137-48.
2003: Pieter K Wierenga; Rita Setroikromo; Gera Kamps; Harm H Kampinga; Edo Vellenga
Differences in heat sensitivity between normal and acute myeloid leukemic stem cells: feasibility of hyperthermic purging of leukemic cells from autologous stem cell grafts.
Experimental hematology 2003;31(5):421-7.
2003: Albertus T J Wierenga; Irma Vogelzang; Bart Eggen; Edo Vellenga
Erythropoietin-induced serine 727 phosphorylation of STAT3 in erythroid cells is mediated by a MEK-, ERK-, and MSK1-dependent pathway.
Experimental hematology 2003;31(5):398-405.
2003: Irene H Heijink; Edo Vellenga; Peter Borger; Dirkje S Postma; Jan G R de Monchy; Henk Kauffman
Polarized Th1 and Th2 cells are less responsive to negative feedback by receptors coupled to the AC/cAMP system compared to freshly isolated T cells.
British journal of pharmacology 2003;138(8):1441-50.
2003: Jeroen Guikema; Sjoerd Hovenga; Edo Vellenga; Jelle J Conradie; Wayel Habib Abdulahad; Roelof Bekkema; Jan W Smit; Fenghuang Zhan; John Shaughnessy; Nicolaas A Bos
CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease.
British journal of haematology 2003;121(1):36-43.
2003: Christine M Segeren; Pieter Sonneveld; Bronno van der Holt; Edo Vellenga; Alexandra J Croockewit; Gregor Verhoef; Jan J Cornelissen; M Ronald Schaafsma; Marinus H J van Oers; Pierre W Wijermans; Wim E Fibbe; Shulamiet Wittebol; Harry C Schouten; Marinus van Marwijk Kooy; Douwe H Biesma; Joke W Baars; Rosalyn Slater; Monique M C Steijaert; Ivonne Buijt; Henk M Lokhorst
Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.
Blood 2003;101(6):2144-51.
2003: Gerald de Haan; Ellen Weersing; Bert Dontje; Ronald van Os; Leonid V Bystrykh; Edo Vellenga; Geraldine Miller
In vitro generation of long-term repopulating hematopoietic stem cells by fibroblast growth factor-1.
Developmental cell 2003;4(2):241-51.
2003: Gwenny M Fuhler; A Lyndsay Drayer; Edo Vellenga
Decreased phosphorylation of protein kinase B and extracellular signal-regulated kinase in neutrophils from patients with myelodysplasia.
Blood 2003;101(3):1172-80.
2003: Sabine L A Plasschaert; Edo Vellenga; Eveline S J M de Bont; Dorina M van der Kolk; Anjo J P Veerman; Wim J Sluiter; S M G J Daenen; Elisabeth G E de Vries; Willem A Kamps
High functional P-glycoprotein activity is more often present in T-cell acute lymphoblastic leukaemic cells in adults than in children.
Leukemia & lymphoma 2003;44(1):85-95.
2002: Albertus T J Wierenga; Bart Eggen; Wiebe Kruijer; Edo Vellenga
Proteolytic degradation of Smad4 in extracts of AML blasts.
Leukemia research 2002;26(12):1105-11.
2002: Ramon Roozendaal; Henk Kauffman; Anne-Jan Dijkhuis; Elisabeth T V Ommen; Dirkje S Postma; Jan G R de Monchy; Edo Vellenga
Interaction between nitric oxide and subsets of human T lymphocytes with differences in glutathione metabolism.
Immunology 2002;107(3):334-9.
2002: Irene H Heijink; Edo Vellenga; Peter Borger; Dirkje S Postma; Jan G R de Monchy; Henk Kauffman
Interleukin-6 promotes the production of interleukin-4 and interleukin-5 by interleukin-2-dependent and -independent mechanisms in freshly isolated human T cells.
Immunology 2002;107(3):316-24.
2002: C S M Oude Nijhuis; S M G J Daenen; Edo Vellenga; Winette T A van der Graaf; Jourik A Gietema; Harry J M Groen; Willem A Kamps; Eveline S J M de Bont
Fever and neutropenia in cancer patients: the diagnostic role of cytokines in risk assessment strategies.
Critical reviews in oncology/hematology 2002;44(2):163-74.
2002: Eveline S J M de Bont; V M E Neefjes; S Rosati; Edo Vellenga; Willem A Kamps
New vessel formation and aberrant VEGF/VEGFR signaling in acute leukemia: does it matter?
Leukemia & lymphoma 2002;43(10):1901-9.
2002: Jeroen Guikema; Edo Vellenga; Marleen Bakkus; Nicolaas A Bos
Myeloma clonotypic B cells are hampered in their ability to undergo B-cell differentiation in vitro.
British journal of haematology 2002;119(1):54-61.
2002: Gerald de Haan; Leonid V Bystrykh; Ellen Weersing; Bert Dontje; Hartmut Geiger; Natalia Ivanova; Ihor R Lemischka; Edo Vellenga; Gary Van Zant
A genetic and genomic analysis identifies a cluster of genes associated with hematopoietic cell turnover.
Blood 2002;100(6):2056-62.
2002: Ingrid I van Gameren; Bouke P C Hazenberg; Pieter L Jager; Jan W Smit; Edo Vellenga
AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2002;9(3):165-74.
2002: Arjen-Kars Boer; A Lyndsay Drayer; Hallgeir Rui; Edo Vellenga
Prostaglandin-E2 enhances EPO-mediated STAT5 transcriptional activity by serine phosphorylation of CREB.
Blood 2002;100(2):467-73.
2002: Estelle Noach; Albertina Ausema; Jan H Dillingh; Bert Dontje; Ellen Weersing; Imre Akkerman; Edo Vellenga; Gerald de Haan
Growth factor treatment prior to low-dose total body irradiation increases donor cell engraftment after bone marrow transplantation in mice.
Blood 2002;100(1):312-7.
2002: Pieter K Wierenga; Rita Setroikromo; Gera Kamps; Harm H Kampinga; Edo Vellenga
Peripheral blood stem cells differ from bone marrow stem cells in cell cycle status, repopulating potential, and sensitivity toward hyperthermic purging in mice mobilized with cyclophosphamide and granulocyte colony-stimulating factor.
Journal of hematotherapy & stem cell research 2002;11(3):523-32.
2002: Henk Louwes; J Th M de Wolf; Ewout J Houwerzijl; Edo Vellenga
Evaluation assays measuring platelet kinetics in bone marrow and peripheral blood. An overview.
Nuclear medicine communications 2002;23(6):581-90.
2002: Dorina M van der Kolk; Edo Vellenga; George L Scheffer; Michael Müller; Susan E Bates; Rik J Scheper; Elisabeth G E de Vries
Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia.
Blood 2002;99(10):3763-70.
2002: Dorina M van der Kolk; Elisabeth G E de Vries; Michael Müller; Edo Vellenga
The role of drug efflux pumps in acute myeloid leukemia.
Leukemia & lymphoma 2002;43(4):685-701.
2002: A Lyndsay Drayer; CT Smit Sibinga; Mariet T Esselink; J Th M de Wolf; Edo Vellenga
In vitro megakaryocyte expansion in patients with delayed platelet engraftment after autologous stem cell transplantation.
Annals of hematology 2002;81(4):192-7.
2002: Albertus T J Wierenga; Jan Jacob Schuringa; Bart Eggen; Wiebe Kruijer; Edo Vellenga
Downregulation of IL-6-induced STAT3 tyrosine phosphorylation by TGF-beta1 is mediated by caspase-dependent and -independent processes.
Leukemia 2002;16(4):675-82.
2002: Francesca Maria Rossi; Massimo Degan; Francesca Tassan Mazzocco; Raffaele Di Francia; Donatella Aldinucci; Dalisa Poletto; Edo Vellenga; Antonio Pinto; Valter Gattei
Co-expression of CD30 ligand and interleukin 4 (IL-4) receptors by acute myeloid leukaemia blasts is associated with the expansion of IL-4-producing CD30+ normal T cells.
British journal of haematology 2002;117(1):59-69.
2002: Jan Jacob Schuringa; Saskia van der Schaaf; Edo Vellenga; Bart Eggen; Wiebe Kruijer
LIF-induced STAT3 signaling in murine versus human embryonal carcinoma (EC) cells.
Experimental cell research 2002;274(1):119-29.
2001: H H Lemmink; L Tuyt; G Knol; E Krikke; Edo Vellenga
Identification of LIL-STAT in monocytic leukemia cells and monocytes after stimulation with interleukin-6 or interferon gamma.
Blood 2001;98(13):3849-52.
2001: Henk Louwes; Edo Vellenga; Ewout J Houwerzijl; J Th M de Wolf
Effects of prednisone and splenectomy in patients with idiopathic thrombocytopenic purpura: only splenectomy induces a complete remission.
Annals of hematology 2001;80(12):728-32.
2001: KU Birkenkamp; Marjan Geugien; HH Lemmink; Wiebe Kruijer; Edo Vellenga
Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts.
Leukemia 2001;15(12):1923-31.
2001: Arjen-Kars Boer; A Lyndsay Drayer; Edo Vellenga
Effects of overexpression of the SH2-containing inositol phosphatase SHIP on proliferation and apoptosis of erythroid AS-E2 cells.
Leukemia 2001;15(11):1750-7.
2001: Eveline S J M de Bont; Jeroen Guikema; Frank Scherpen; T Meeuwsen; Willem A Kamps; Edo Vellenga; Nicolaas A Bos
Mobilized human CD34+ hematopoietic stem cells enhance tumor growth in a nonobese diabetic/severe combined immunodeficient mouse model of human non-Hodgkin's lymphoma.
Cancer research 2001;61(20):7654-9.
2001: Henk Louwes; Edo Vellenga; J Th M de Wolf
Abnormal platelet adhesion on abdominal vessels in asymptomatic patients with paroxysmal nocturnal hemoglobinuria.
Annals of hematology 2001;80(10):573-6.
2001: Dorina M van der Kolk; Elisabeth G E de Vries; L Noordhoek; Eva van den Berg; M A van der Pol; Michael Müller; Edo Vellenga
Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia.
Leukemia 2001;15(10):1544-53.
2001: Michel van Agthoven; Edo Vellenga; W E Fibbe; T Kingma; Carin A Uyl-de Groot
Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. a prospective randomised trial.
European journal of cancer (Oxford, England : 1990) 2001;37(14):1781-9.
2001: Jan Jacob Schuringa; K Wojtachnio; W Hagens; Edo Vellenga; C H Buys; R Hofstra; Wiebe Kruijer
MEN2A-RET-induced cellular transformation by activation of STAT3.
Oncogene 2001;20(38):5350-8.
2001: Eveline S J M de Bont; C S M Oude Nijhuis; Willem A Kamps; Edo Vellenga
Interpretation of inflammatory markers in feverish cancer patients with or without neutropenia at admission.
British journal of haematology 2001;114(2):489-91.
2001: Edo Vellenga; Michel van Agthoven; Alexandra J Croockewit; Leo F Verdonck; P J Wijermans; Marinus H J van Oers; Corine P Volkers; Gustaaf W van Imhoff; T Kingma; Carin A Uyl-de Groot; W E Fibbe
Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study.
British journal of haematology 2001;114(2):319-26.
2001: Jan Jacob Schuringa; Lodewijk Dekker; Edo Vellenga; Wiebe Kruijer
Sequential activation of Rac-1, SEK-1/MKK-4, and protein kinase Cdelta is required for interleukin-6-induced STAT3 Ser-727 phosphorylation and transactivation.
The Journal of biological chemistry 2001;276(29):27709-15.
2001: Eveline S J M de Bont; S Rosati; S Jacobs; Willem A Kamps; Edo Vellenga
Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor.
British journal of haematology 2001;113(2):296-304.
2001: AA Van De Loosdrecht; S J L Brada; Nel R Blom; DW Hendriks; Jan W Smit; Eva van den Berg; J Th M de Wolf; Edo Vellenga
Mitochondrial disruption and limited apoptosis of erythroblasts are associated with high risk myelodysplasia. An ultrastructural analysis.
Leukemia research 2001;25(5):385-93.
2001: Jan Jacob Schuringa; H Timmer; D Luttickhuizen; Edo Vellenga; Wiebe Kruijer
c-Jun and c-Fos cooperate with STAT3 in IL-6-induced transactivation of the IL-6 respone element (IRE).
Cytokine 2001;14(2):78-87.
2001: Jan Jacob Schuringa; Hein Schepers; Edo Vellenga; Wiebe Kruijer
Ser727-dependent transcriptional activation by association of p300 with STAT3 upon IL-6 stimulation.
FEBS letters 2001;495(1-2):71-6.
2001: Ramon Roozendaal; Edo Vellenga; M A de Jong; K F Traanberg; Dirkje S Postma; Jan G R de Monchy; Henk Kauffman
Resistance of activated human Th2 cells to NO-induced apoptosis is mediated by gamma-glutamyltranspeptidase.
International immunology 2001;13(4):519-28.
2001: Anneke G Bosga-Bouwer; D Hendriks; Edo Vellenga; H Zorgdrager; Eva van den Berg
Cytogenetic analysis of cryopreserved bone marrow cells.
Cancer genetics and cytogenetics 2001;124(2):165-8.
2000: Pieter K Wierenga; Rita Setroikromo; Edo Vellenga; Harm H Kampinga
Purging of acute myeloid leukaemia cells from stem cell grafts by hyperthermia: enhancement of the therapeutic index by the tetrapeptide AcSDKP and the alkyl-lysophospholipid ET-18-OCH(3).
British journal of haematology 2000;111(4):1145-52.
2000: KU Birkenkamp; Mariet T Esselink; Wiebe Kruijer; Edo Vellenga
An inhibitor of PI3-K differentially affects proliferation and IL-6 protein secretion in normal and leukemic myeloid cells depending on the stage of differentiation.
Experimental hematology 2000;28(11):1239-49.
2000: A A van de Loosdrecht; Klaas Kok; Bonnie de Vries; Anneke Y van der Veen; Eva van den Berg; M T Esselink; P Marynen; Edo Vellenga; Gustaaf W van Imhoff
Breakpoint analysis by fluorescence in situ hybridization in myelodysplastic syndromes with t(3;12)(q26;p13) and expression of EVI1.
Leukemia 2000;14(10):1857-8.
2000: KU Birkenkamp; LM Tuyt; C Lummen; Albertus T J Wierenga; Wiebe Kruijer; Edo Vellenga
The p38 MAP kinase inhibitor SB203580 enhances nuclear factor-kappa B transcriptional activity by a non-specific effect upon the ERK pathway.
British journal of pharmacology 2000;131(1):99-107.
2000: Dorina M van der Kolk; Elisabeth G E de Vries; W J van Putten; Leo F Verdonck; Gert Ossenkoppele; Gregor Verhoef; Edo Vellenga
P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(8):3205-14.
2000: P Willems; O Verhagen; Christine M Segeren; P Veenhuizen; J Guikema; E Wiemer; L Groothuis; T B Jong; H Kok; Andries C Bloem; N Bos; Edo Vellenga; E J B M Mensink; Pieter Sonneveld; Henk M Lokhorst; E van Der Schoot; Reinier A P Raymakers
Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study. Belgium-Dutch Hematology-Oncology Group.
Blood 2000;96(1):63-70.
2000: Peter Borger; Dirkje S Postma; Edo Vellenga; Henk Kauffman
Regulation of asthma-related T-cell cytokines by the cyclic AMP-dependent signalling pathway.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2000;30(7):920-6.
2000: Jan Jacob Schuringa; Albertus T J Wierenga; Wiebe Kruijer; Edo Vellenga
Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6.
Blood 2000;95(12):3765-70.
2000: A Lyndsay Drayer; C T Sibinga; Nel R Blom; J Th M de Wolf; Edo Vellenga
The in vitro effects of cytokines on expansion and migration of megakaryocyte progenitors.
British journal of haematology 2000;109(4):776-84.
2000: J J W M Janssen; R S van Rijn; Bronno van der Holt; Gerrit J Schuurhuis; Edo Vellenga; Gregor Verhoef; Gert Ossenkoppele; Eva van den Berg; A Hagemeijer; R Släter; A W M Nieuwint; Jan J Cornelissen
Mobilisation of haemopoietic progenitors in CML: a second course of intensive chemotherapy does not improve Ph-negativity in stem cell harvests.
Bone marrow transplantation 2000;25(11):1147-55.
2000: Dorina M van der Kolk; Edo Vellenga; Anneke Y van der Veen; L Noordhoek; Hetty Timmer-Bosscha; Gert Ossenkoppele; R A Raymakers; Michael Müller; Eva van den Berg; Elisabeth G E de Vries
Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity.
Blood 2000;95(11):3514-9.
2000: Sjoerd Hovenga; J Th M de Wolf; Jeroen Guikema; Harrie G Klip; Jan W Smit; CT Smit Sibinga; Nicolaas A Bos; Edo Vellenga
Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation.
Bone marrow transplantation 2000;25(7):723-8.
2000: Jan Jacob Schuringa; LJ Jonk; Wim H A Dokter; Edo Vellenga; Wiebe Kruijer
Interleukin-6-induced STAT3 transactivation and Ser727 phosphorylation involves Vav, Rac-1 and the kinase SEK-1/MKK-4 as signal transduction components.
The Biochemical journal 2000;347 Pt 1():89-96.
2000: Hannie Sietsma; Robert Jan Veldman; D Kolk; B Ausema; W Nijhof; Willem A Kamps; Edo Vellenga; Jan Willem Kok
1-phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(3):942-8.
2000: AA Van De Loosdrecht; Edo Vellenga
Myelodysplasia and apoptosis: new insights into ineffective erythropoiesis.
Medical oncology (Northwood, London, England) 2000;17(1):16-21.
2000: P Nieboer; Edo Vellenga; R Adriaanse; AA van de Loosdrecht
Central diabetes insipidus preceding acute myeloid leukemia with t(3;12)(q26;p12).
The Netherlands journal of medicine 2000;56(2):45-7.
2000: AA Van De Loosdrecht; DW Hendriks; Nel R Blom; Jan W Smit; J Th M de Wolf; Edo Vellenga
Excessive apoptosis of bone marrow erythroblasts in a patient with autoimmune haemolytic anaemia with reticulocytopenia.
British journal of haematology 2000;108(2):313-5.
1999: KU Birkenkamp; Mariet T Esselink; Wiebe Kruijer; Edo Vellenga
Differential effects of interleukin-3 and interleukin-1 on the proliferation and interleukin-6 protein secretion of acute myeloid leukemic cells; the involvement of ERK, p38 and STAT5.
European cytokine network 1999;10(4):479-90.
1999: Ramon Roozendaal; Edo Vellenga; Dirkje S Postma; Jan G R de Monchy; Henk Kauffman
Nitric oxide selectively decreases interferon-gamma expression by activated human T lymphocytes via a cGMP-independent mechanism.
Immunology 1999;98(3):393-9.
1999: Peter Borger; Gerard H Koëter; J André B Timmerman; Edo Vellenga; J F C Tomee; Henk Kauffman
Proteases from Aspergillus fumigatus induce interleukin (IL)-6 and IL-8 production in airway epithelial cell lines by transcriptional mechanisms.
The Journal of infectious diseases 1999;180(4):1267-74.
1999: J G Asschert; Edo Vellenga; M H Ruiters; Elisabeth G E de Vries
Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines.
International journal of cancer. Journal international du cancer 1999;82(2):244-9.
1999: Hannie Sietsma; Willem A Kamps; Bert Dontje; D Hendriks; Jan Willem Kok; Edo Vellenga; W Nijhof
Leukemia-induced bone marrow depression: effects of gangliosides on erythroid cell production.
International journal of cancer. Journal international du cancer 1999;82(1):92-7.
1999: KU Birkenkamp; Wim H A Dokter; Mariet T Esselink; LJ Jonk; Wiebe Kruijer; Edo Vellenga
A dual function for p38 MAP kinase in hematopoietic cells: involvement in apoptosis and cell activation.
Leukemia 1999;13(7):1037-45.
1999: Peter Borger; G J Jonker; Edo Vellenga; Dirkje S Postma; Jan G R de Monchy; Henk Kauffman
Allergen challenge primes for IL-5 mRNA production and abrogates beta-adrenergic function in peripheral blood T lymphocytes from asthmatics.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 1999;29(7):933-40.
1999: Edo Vellenga; Wim L J van Putten; Marc Boogaerts; S M G J Daenen; Gregor Verhoef; Anton Hagenbeek; Andries R Jonkhoff; Peter C Huijgens; Leo F Verdonck; Johannes Van Der Lelie; Harry C Schouten; Jürg Gmür; Pierre W Wijermans; Alois Gratwohl; U Hess; M F Fey; Bob Löwenberg
Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia?
Bone marrow transplantation 1999;23(12):1279-82.
1999: Peter Borger; Nick H T Ten Hacken; Edo Vellenga; Henk Kauffman; Dirkje S Postma
Peripheral blood T lymphocytes from asthmatic patients are primed for enhanced expression of interleukin (IL)-4 and IL-5 mRNA: associations with lung function and serum IgE.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 1999;29(6):772-9.
1999: Edo Vellenga; LM Tuyt; B J Wierenga; Michael Müller; Wim H A Dokter
Interleukin-6 production by activated human monocytic cells is enhanced by MK-571, a specific inhibitor of the multi-drug resistance protein-1.
British journal of pharmacology 1999;127(2):441-8.
1999: LM Tuyt; Wim H A Dokter; KU Birkenkamp; S B Koopmans; C Lummen; Wiebe Kruijer; Edo Vellenga
Extracellular-regulated kinase 1/2, Jun N-terminal kinase, and c-Jun are involved in NF-kappa B-dependent IL-6 expression in human monocytes.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(8):4893-902.
1999: JG Asschert; Elisabeth G E de Vries; Steven de Jong; Sebo Withoff; Edo Vellenga
Differential regulation of IL-6 promoter activity in a human ovarian-tumor cell line transfected with various p53 mutants: involvement of AP-1.
International journal of cancer. Journal international du cancer 1999;81(2):236-42.
1999: A W Kamps; D Hendriks; Jan W Smit; Edo Vellenga
Role of macrophage colony-stimulating factor in the differentiation and expansion of monocytes and dendritic cells from CD34+ progenitor cells.
Medical oncology (Northwood, London, England) 1999;16(1):46-52.
1999: Christine M Segeren; Pieter Sonneveld; Bronno van der Holt; Joke W Baars; Douwe H Biesma; J J Cornellissen; Alexandra J Croockewit; Adriaan W Dekker; W E Fibbe; Bob Löwenberg; Marinus van Marwijk Kooy; Marinus H J van Oers; D J Richel; H C Schouten; Edo Vellenga; Gregor Verhoef; Pierre W Wijermans; Shulamiet Wittebol; Henk M Lokhorst
Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma.
British journal of haematology 1999;105(1):127-30.
1999: Henk Louwes; O A Zeinali Lathori; Edo Vellenga; J Th M de Wolf
Platelet kinetic studies in patients with idiopathic thrombocytopenic purpura.
The American journal of medicine 1999;106(4):430-4.
1999: Jeroen Guikema; Edo Vellenga; J M Veeneman; Sjoerd Hovenga; Marleen Bakkus; Harrie G Klip; Nicolaas A Bos
Multiple myeloma related cells in patients undergoing autologous peripheral blood stem cell transplantation.
British journal of haematology 1999;104(4):748-54.
1999: Peter Borger; Henk Kauffman; Dirkje S Postma; Mariet T Esselink; Edo Vellenga
Interleukin-15 differentially enhances the expression of interferon-gamma and interleukin-4 in activated human (CD4+) T lymphocytes.
Immunology 1999;96(2):207-14.
1999: Dorina M van der Kolk; Edo Vellenga; Michael Müller; Elisabeth G E de Vries
Multidrug resistance protein MRP1, glutathione, and related enzymes. Their importance in acute myeloid leukemia.
Advances in experimental medicine and biology 1999;457():187-98.
1998: Hannie Sietsma; W Nijhof; Bert Dontje; Edo Vellenga; Willem A Kamps; Jan Willem Kok
Inhibition of hemopoiesis in vitro by neuroblastoma-derived gangliosides.
Cancer research 1998;58(21):4840-4.
1998: Peter Borger; Y Hoekstra; Mariet T Esselink; Dirkje S Postma; Johan Zaagsma; Edo Vellenga; Henk Kauffman
Beta-adrenoceptor-mediated inhibition of IFN-gamma, IL-3, and GM-CSF mRNA accumulation in activated human T lymphocytes is solely mediated by the beta2-adrenoceptor subtype.
American journal of respiratory cell and molecular biology 1998;19(3):400-7.
1998: LM Tuyt; K Bregman; C Lummen; Wim H A Dokter; Edo Vellenga
Differential binding activity of the transcription factor LIL-STAT in immature and differentiated normal and leukemic myeloid cells.
Blood 1998;92(4):1364-73.
1998: Dorina M van der Kolk; Elisabeth G E de Vries; J A Koning; Eva van den Berg; Michael Müller; Edo Vellenga
Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(7):1727-36.
1998: S J L Brada; J Th M de Wolf; DW Hendriks; Jan W Smit; Edo Vellenga
CD34+/CD36- cells from myelodysplasia patients have a limited capacity to proliferate but can differentiate in response to Epo and MGF stimulation.
Leukemia 1998;12(6):882-6.
1998: JG Asschert; Edo Vellenga; Steven de Jong; Elisabeth G E de Vries
Mutual interactions between p53 and growth factors in cancer.
Anticancer research 1998;18(3A):1713-25.
1998: S J L Brada; J Th M de Wolf; S Poppema; Edo Vellenga
Ischaemic colitis and lung infiltrates caused by extramedullary haematopoiesis in a patient with an acute erythroid leukaemia following polycythaemia vera.
The Netherlands journal of medicine 1998;52(4):142-6.
1998: Carin A Uyl-de Groot; Bob Löwenberg; Edo Vellenga; Stefan Suciu; R Willemze; Frans F H Rutten
Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia.
British journal of haematology 1998;100(4):629-36.
1998: H de Wit; Wim H A Dokter; S B Koopmans; C Lummen; M van der Leij; Jan W Smit; Edo Vellenga
Regulation of p100 (NFKB2) expression in human monocytes in response to inflammatory mediators and lymphokines.
Leukemia 1998;12(3):363-70.
1998: S J L Brada; J Th M de Wolf; DW Hendriks; Henk Louwes; Eva van den Berg; Edo Vellenga
Characterization of the erythropoiesis in myelodysplasia by means of ferrokinetic studies, in vitro erythroid colony formation and soluble transferrin receptor.
Leukemia 1998;12(3):340-5.
1998: Sonja I Gringhuis; Lou F M H De Leij; Paul J Coffer; Edo Vellenga
Signaling through CD5 activates a pathway involving phosphatidylinositol 3-kinase, Vav, and Rac1 in human mature T lymphocytes.
Molecular and cellular biology 1998;18(3):1725-35.
1998: Peter Borger; Edo Vellenga; Sonja I Gringhuis; J André B Timmerman; C Lummen; Dirkje S Postma; Henk Kauffman
Prostaglandin E2 differentially modulates IL-5 gene expression in activated human T lymphocytes depending on the costimulatory signal.
The Journal of allergy and clinical immunology 1998;101(2 Pt 1):231-40.
1998: S M G J Daenen; Gustaaf W van Imhoff; Eva van den Berg; P J de Kam; H Haaxma-Reiche; Edo Vellenga; Jan W Smit; R M Halie
Improved outcome of adult acute lymphoblastic leukaemia by moderately intensified chemotherapy which includes a 'pre-induction' course for rapid tumour reduction: preliminary results on 66 patients.
British journal of haematology 1998;100(2):273-82.
1997: Sonja I Gringhuis; Lou F M H De Leij; Gary Wayman; Hiroshi Tokumitsu; Edo Vellenga
The Ca2+/calmodulin-dependent kinase type IV is involved in the CD5-mediated signaling pathway in human T lymphocytes.
The Journal of biological chemistry 1997;272(50):31809-20.
1997: LM Tuyt; Wim H A Dokter; Edo Vellenga
Gene expression, biological effects and clinical aspects of lymphokines.
Critical reviews in oncology/hematology 1997;26(3):175-213.
1997: Bob Löwenberg; Marc Boogaerts; S M G J Daenen; Gregor Verhoef; Anton Hagenbeek; Edo Vellenga; Gert Ossenkoppele; Peter C Huijgens; Leo F Verdonck; Johannes Van Der Lelie; JJ Wielenga; Harry C Schouten; Jürg Gmür; Alois Gratwohl; U Hess; M F Fey; Wim L J van Putten
Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(12):3496-506.
1997: JG Asschert; Edo Vellenga; Harry Hollema; Ate G J van der Zee; Elisabeth G E de Vries
Expression of macrophage colony-stimulating factor (M-CSF), interleukin-6, (IL-6), interleukin-1 beta (IL-1 beta), interleukin-11 (IL-11) and tumour necrosis factor-alpha (TNF-alpha) in p53-characterised human ovarian carcinomas.
European journal of cancer (Oxford, England : 1990) 1997;33(13):2246-51.
1997: Sjoerd Hovenga; J Th M de Wolf; Harrie G Klip; Edo Vellenga
Consolidation therapy with autologous stem cell transplantation in plasma cell leukemia after VAD, high-dose cyclophosphamide and EDAP courses: a report of three cases and a review of the literature.
Bone marrow transplantation 1997;20(10):901-4.
1997: Sonja I Gringhuis; Lou F M H De Leij; E W Verschuren; Peter Borger; Edo Vellenga
Interleukin-7 upregulates the interleukin-2-gene expression in activated human T lymphocytes at the transcriptional level by enhancing the DNA binding activities of both nuclear factor of activated T cells and activator protein-1.
Blood 1997;90(7):2690-700.
1997: J Asschert; E de Vries; Dorina M van der Kolk; Michael Müller; Edo Vellenga
The combined effects of IL-3 and PSC 833 on daunorubicin- and mitoxantrone cytotoxicity in two growth factor-dependent leukemic cell lines.
Leukemia 1997;11(5):680-6.
1997: Bob Löwenberg; Wim L J van Putten; A Ferrant; Gert Ossenkoppele; Edo Vellenga; Leo F Verdonck; A Gratwohl; M A Boogaerts
Peripheral blood progenitor cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia.
Stem cells (Dayton, Ohio) 1997;15 Suppl 1():177-80; discussion 181.
1996: Wim H A Dokter; S B Koopmans; Edo Vellenga
Effects of IL-10 and IL-4 on LPS-induced transcription factors (AP-1, NF-IL6 and NF-kappa B) which are involved in IL-6 regulation.
Leukemia 1996;10(8):1308-16.
1996: S J L Brada; J Th M de Wolf; D Hendriks; Mariet T Esselink; Marcel H J Ruiters; Edo Vellenga
The supportive effects of erythropoietin and mast cell growth factor on CD34+/CD36- sorted bone marrow cells of myelodysplasia patients.
Blood 1996;88(2):505-10.
1996: G J Veldhuis; A H van der Leest; J Th M de Wolf; Elisabeth G E de Vries; Edo Vellenga
A case of localized Castleman's disease with systemic involvement: treatment and pathogenetic aspects.
Annals of hematology 1996;73(1):47-50.
1996: LM Tuyt; H De Wit; S B Koopmans; S J Sierdsema; Edo Vellenga
Effects of IL-3 and LPS on transcription factors involved in the regulation of IL-6 mRNA.
British journal of haematology 1996;92(3):521-9.
1996: Peter Borger; Henk Kauffman; Dirkje S Postma; Edo Vellenga
IL-7 differentially modulates the expression of IFN-gamma and IL-4 in activated human T lymphocytes by transcriptional and post-transcriptional mechanisms.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(4):1333-8.
1996: H de Wit; D Hoogstraten; R M Halie; Edo Vellenga
Interferon-gamma modulates the lipopolysaccharide-induced expression of AP-1 and NF-kappa B at the mRNA and protein level in human monocytes.
Experimental hematology 1996;24(2):228-35.
1996: Peter Borger; Henk Kauffman; J L Vijgen; Dirkje S Postma; Edo Vellenga
Activation of the cAMP-dependent signaling pathway downregulates the expression of interleukin-3 and granulocyte-macrophage colony-stimulating factor in activated human T lymphocytes.
Experimental hematology 1996;24(2):108-15.
1996: Edo Vellenga; Carin A Uyl-de Groot; R de Wit; H J Keizer; Bob Löwenberg; M A ten Haaft; Theo de Witte; C A Verhagen; Gerrit Stoter; Frans F H Rutten; Nanno H Mulder; w martin smid; Elisabeth G E de Vries
Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(2):619-27.
1996: Peter Borger; Henk Kauffman; Dirkje S Postma; Edo Vellenga
Interleukin-4 gene expression in activated human T lymphocytes is regulated by the cyclic adenosine monophosphate-dependent signaling pathway.
Blood 1996;87(2):691-8.
1996: Carin A Uyl-de Groot; Edo Vellenga; Frans F H Rutten
An economic model to assess the savings from a clinical application of haematopoietic growth factors.
European journal of cancer (Oxford, England : 1990) 1996;32A(1):57-62.
1996: J J Wielenga; Edo Vellenga; A Groenewegen; Pieter Sonneveld; Bob Löwenberg
Recombinant human interleukin-3 (rH IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II study.
Leukemia 1996;10(1):43-7.
1995: H de Graaf; Nanno H Mulder; P H B Willemse; Winette T A van der Graaf; Dirk T Sleijfer; Jan G Zijlstra; M Elias; C T Sibinga; Edo Vellenga; Elisabeth G E de Vries
The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
Anticancer research 1995;15(6B):2851-6.
1995: J Nieken; Nanno H Mulder; J Buter; Edo Vellenga; Pieter C Limburg; D A Piers; Elisabeth G E de Vries
Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients.
Blood 1995;86(3):900-5.
1995: LM Tuyt; Wim H A Dokter; Mariet T Esselink; Edo Vellenga
Divergent effects of IL-10 and IL-4 on the proliferation and growth factor secretion by acute myeloblastic leukemic cells.
European cytokine network 1995;6(4):231-5.
1995: Wim H A Dokter; LM Tuyt; S J Sierdsema; Mariet T Esselink; Edo Vellenga
The spontaneous expression of interleukin-1 beta and interleukin-6 is associated with spontaneous expression of AP-1 and NF-kappa B transcription factor in acute myeloblastic leukemia cells.
Leukemia 1995;9(3):425-32.
1995: E W Muller; J Th M de Wolf; R Egger; P W Wijermans; P C Huijgens; M R Halie; Edo Vellenga
Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera.
British journal of haematology 1995;89(2):313-8.
1995: H van Kamp; Gustaaf W van Imhoff; J Th M de Wolf; Jan W Smit; M R Halie; Edo Vellenga
The effect of cyclosporine on haematological parameters in patients with paroxysmal nocturnal haemoglobinuria.
British journal of haematology 1995;89(1):79-82.
1994: A Sprikkelman; J Th M de Wolf; Edo Vellenga
The application of hematopoietic growth factors in drug-induced agranulocytosis: a review of 70 cases.
Leukemia 1994;8(12):2031-6.
1994: Winette T A van der Graaf; Elisabeth G E de Vries; Hetty Timmer-Bosscha; Gert Jan Meersma; G Mesander; Edo Vellenga; Nanno H Mulder
Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines.
Cancer research 1994;54(20):5368-73.
1994: J Th M de Wolf; D W Hendriks; Mariet T Esselink; M R Halie; Edo Vellenga
The effects of IL-1 and IL-4 on the Epo-independent erythroid progenitor in polycythaemia vera.
British journal of haematology 1994;88(2):242-6.
1994: M M van Gameren; P H B Willemse; Nanno H Mulder; Pieter C Limburg; H J Groen; Edo Vellenga; Elisabeth G E de Vries
Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study.
Blood 1994;84(5):1434-41.
1994: H de Wit; D W Hendriks; M R Halie; Edo Vellenga
Interleukin-4 receptor regulation in human monocytic cells.
Blood 1994;84(2):608-15.
1994: Wim H A Dokter; S J Sierdsema; Mariet T Esselink; M R Halie; Edo Vellenga
Interleukin-4-mediated inhibition of C-Fos mRNA expression: role of the lipoxygenase directed pathway.
Leukemia 1994;8(7):1181-4.
1994: J Th M de Wolf; E W Muller; D H Hendriks; R M Halie; Edo Vellenga
Mast cell growth factor modulates CD36 antigen expression on erythroid progenitors from human bone marrow and peripheral blood associated with ongoing differentiation.
Blood 1994;84(1):59-64.
1994: Wim H A Dokter; Ate Dijkstra; S B Koopmans; A B Mulder; B K Stulp; M R Halie; W Keck; Edo Vellenga
G(AnH)MTetra, a naturally occurring 1,6-anhydro muramyl dipeptide, induces granulocyte colony-stimulating factor expression in human monocytes: a molecular analysis.
Infection and immunity 1994;62(7):2953-7.
1994: H van Kamp; Jan W Smit; E van den Berg; M Ruud Halie; Edo Vellenga
Myelodysplasia following paroxysmal nocturnal haemoglobinuria: evidence for the emergence of a separate clone.
British journal of haematology 1994;87(2):399-400.
1994: Jeannette F M van Straaten; Wim H A Dokter; B K Stulp; Edo Vellenga
The regulation of interleukin 5 and interleukin 3 gene expression in human T cells.
Cytokine 1994;6(3):229-34.
1994: Wim H A Dokter; Ate Dijkstra; S B Koopmans; B K Stulp; W Keck; M R Halie; Edo Vellenga
G(Anh)MTetra, a natural bacterial cell wall breakdown product, induces interleukin-1 beta and interleukin-6 expression in human monocytes. A study of the molecular mechanisms involved in inflammatory cytokine expression.
The Journal of biological chemistry 1994;269(6):4201-6.
1994: H de Wit; Mariet T Esselink; M R Halie; Edo Vellenga
Differential regulation of M-CSF and IL-6 gene expression in monocytic cells.
British journal of haematology 1994;86(2):259-64.
1994: Wim H A Dokter; S J Sierdsema; Mariet T Esselink; M R Halie; Edo Vellenga
Interleukin-4 mRNA and protein in activated human T cells are enhanced by interleukin-7.
Experimental hematology 1994;22(1):74-9.
1994: Edo Vellenga
In vitro growth behaviour of acute myeloid leukaemic cells.
European journal of cancer (Oxford, England : 1990) 1994;30A(10):1407-8.
1994: gerjan navis; R P F Dullaart; Edo Vellenga; J D Elema; Paul E de Jong
Renal disease in POEMS syndrome: report on a case and review of the literature.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1994;9(10):1477-81.
1993: G A Hospers; J Th M de Wolf; Bouke P C Hazenberg; Edo Vellenga
[Hematopoietic growth factors as supportive treatment in drug-induced agranulocytosis].
Nederlands tijdschrift voor geneeskunde 1993;137(42):2152-4.
1993: E W Muller; J Th M de Wolf; D W Hendriks; Mariet T Esselink; M R Halie; Edo Vellenga
Recombinant human mast cell growth factor supports erythroid colony formation in polycythemia vera in the presence and absence of erythropoietin and serum.
Experimental hematology 1993;21(10):1353-7.
1993: Edo Vellenga; Wim H A Dokter; R M Halie
Interleukin-4 and its receptor; modulating effects on immature and mature hematopoietic cells.
Leukemia 1993;7(8):1131-41.
1993: H de Wit; Wim H A Dokter; Mariet T Esselink; M R Halie; Edo Vellenga
Interferon-gamma enhances the LPS-induced G-CSF gene expression in human adherent monocytes, which is regulated at transcriptional and posttranscriptional levels.
Experimental hematology 1993;21(6):785-90.
1993: Wim H A Dokter; S J Sierdsema; Mariet T Esselink; M R Halie; Edo Vellenga
IL-7 enhances the expression of IL-3 and granulocyte-macrophage-CSF mRNA in activated human T cells by post-transcriptional mechanisms.
Journal of immunology (Baltimore, Md. : 1950) 1993;150(7):2584-90.
1993: Wim H A Dokter; Mariet T Esselink; M R Halie; Edo Vellenga
Interleukin-4 inhibits the lipopolysaccharide-induced expression of c-jun and c-fos messenger RNA and activator protein-1 binding activity in human monocytes.
Blood 1993;81(2):337-43.
1993: E W Muller; J Th M de Wolf; Edo Vellenga
Successful immunosuppressive treatment after failure of erythropoietin therapy in two subjects with refractory anaemia.
British journal of haematology 1993;83(1):171-2.
1993: Wim H A Dokter; Mariet T Esselink; S J Sierdsema; M R Halie; Edo Vellenga
Transcriptional and posttranscriptional regulation of the interleukin-4 and interleukin-3 genes in human T cells.
Blood 1993;81(1):35-40.
1992: J Th M de Wolf; Edo Vellenga; M R Halie
Polycythaemia vera.
The Netherlands journal of medicine 1992;41(5-6):295-304.
1992: Wim H A Dokter; Peter Borger; D Hendriks; I van der Horst; M R Halie; Edo Vellenga
Interleukin-4 (IL-4) receptor expression on human T cells is affected by different intracellular signaling pathways and by IL-4 at transcriptional and posttranscriptional level.
Blood 1992;80(11):2721-8.
1992: Edo Vellenga; Mariet T Esselink; J Straaten; B K Stulp; J Th M de Wolf; R Brons; J Giannotti; Jan W Smit; M R Halie
The supportive effects of IL-7 on eosinophil progenitors from human bone marrow cells can be blocked by anti-IL-5.
Journal of immunology (Baltimore, Md. : 1950) 1992;149(9):2992-5.
1992: A J Wagteveld; Mariet T Esselink; P Limburg; M R Halie; Edo Vellenga
The effects of IL-1 beta and IL-4 on the proliferation and endogenous secretion of growth factors by acute myeloblastic leukemic cells.
Leukemia 1992;6(10):1020-4.
1992: Bonne Biesma; P H B Willemse; Nanno H Mulder; Dirk T Sleijfer; Jourik A Gietema; R Mull; Pieter C Limburg; J Bouma; Edo Vellenga; Elisabeth G E de Vries
Effects of interleukin-3 after chemotherapy for advanced ovarian cancer.
Blood 1992;80(5):1141-8.
1992: Bonne Biesma; Edo Vellenga; P H B Willemse; Elisabeth G E de Vries
Effects of hematopoietic growth factors on chemotherapy-induced myelosuppression.
Critical reviews in oncology/hematology 1992;13(2):107-34.
1992: A B Mulder; J Th M de Wolf; Jan W Smit; J W van Oostveen; Edo Vellenga
Correction of neutropenia by GM-CSF in patients with a large granular lymphocyte proliferation.
Annals of hematology 1992;65(2):91-5.
1992: Pieter E Postmus; Jourik A Gietema; O Damsma; Bonne Biesma; Pieter C Limburg; Edo Vellenga; Elisabeth G E de Vries
Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose-finding study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(7):1131-40.
1992: Jourik A Gietema; Pieter E Postmus; Bonne Biesma; Pieter C Limburg; Edo Vellenga; E G de Vries
Acute-phase response in patients given rhIL-3 after chemotherapy.
Lancet 1992;339(8809):1616-7.
1992: Ernst J Kuipers; Edo Vellenga; J Th M de Wolf; Bouke P C Hazenberg
Sulfasalazine induced agranulocytosis treated with granulocyte-macrophage colony stimulating factor.
The Journal of rheumatology 1992;19(4):621-2.
1991: J Th M de Wolf; D W Hendriks; J A Beentjes; Mariet T Esselink; Jan W Smit; M R Halie; Edo Vellenga
Erythroid progenitors in polycythemia vera demonstrate a different response pattern to IL-4 compared to the normal BFU-E from peripheral blood.
Experimental hematology 1991;19(9):888-92.
1991: A J Wagteveld; A K van Zanten; Mariet T Esselink; M R Halie; Edo Vellenga
Expression and regulation of IL-4 receptors on human monocytes and acute myeloblastic leukemic cells.
Leukemia 1991;5(9):782-8.
1991: Edo Vellenga; Wim H A Dokter; J Th M de Wolf; B van de Vinne; Mariet T Esselink; M R Halie
Interleukin-4 prevents the induction of G-CSF mRNA in human adherent monocytes in response to endotoxin and IL-1 stimulation.
British journal of haematology 1991;79(1):22-6.
1991: E G de Vries; P H Willemse; Bonne Biesma; A C Stern; Pieter C Limburg; Edo Vellenga
Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy.
Lancet 1991;338(8765):517-8.
1991: A S Dofferhoff; Edo Vellenga; Pieter C Limburg; A van Zanten; P O Mulder; J Weits
Tumour necrosis factor (cachectin) and other cytokines in septic shock: a review of the literature.
The Netherlands journal of medicine 1991;39(1-2):45-62.
1991: Winette T A van der Graaf; Elisabeth G E de Vries; D R A Uges; A G Nanninga; Chris J L M Meijer; Edo Vellenga; P O Mulder; Nanno H Mulder
In vitro and in vivo modulation of multi-drug resistance with amiodarone.
International journal of cancer. Journal international du cancer 1991;48(4):616-22.
1991: Harry C Schouten; Edo Vellenga; D J van Rhenen; J Th M de Wolf; P J Coppens; G H Blijham
Recombinant human erythropoietin in patients with myelodysplastic syndromes.
Leukemia 1991;5(5):432-6.
1991: Edo Vellenga; B van der Vinne; J Th M de Wolf; M R Halie
Simultaneous expression and regulation of G-CSF and IL-6 mRNA in adherent human monocytes and fibroblasts.
British journal of haematology 1991;78(1):14-8.
1991: Bonne Biesma; P H B Willemse; Edo Vellenga; Pieter C Limburg; Jan G Aalders; E G de Vries
[The hematopoietic growth factor GM-CSF in chemotherapy for ovarian carcinoma].
Nederlands tijdschrift voor geneeskunde 1991;135(10):420-4.
1991: J Th M de Wolf; D W Hendriks; R C Egger; Mariet T Esselink; M R Halie; Edo Vellenga
Alpha-interferon for intractable pruritus in polycythaemia vera.
Lancet 1991;337(8735):241.
1991: Elisabeth G E de Vries; Bonne Biesma; P H B Willemse; Nanno H Mulder; A C Stern; Jan G Aalders; Edo Vellenga
A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma.
Cancer research 1991;51(1):116-22.
1991: Edo Vellenga; Bonne Biesma; C Meyer; L Wagteveld; Mariet T Esselink; Elisabeth G E de Vries
The effects of five hematopoietic growth factors on human small cell lung carcinoma cell lines: interleukin 3 enhances the proliferation in one of the eleven cell lines.
Cancer research 1991;51(1):73-6.
1990: Edo Vellenga; P C Das
Hematopoietic growth factors.
The International journal of artificial organs 1990;13(7):407-8.
1990: J Th M de Wolf; J A Beentjes; Mariet T Esselink; Jan W Smit; M R Halie; Edo Vellenga
Interleukin-4 suppresses the interleukin-3 dependent erythroid colony formation from normal human bone marrow cells.
British journal of haematology 1990;74(3):246-50.
1990: Edo Vellenga; J Th M de Wolf; J A Beentjes; Mariet T Esselink; Jan W Smit; M R Halie
Divergent effects of interleukin-4 (IL-4) on the granulocyte colony-stimulating factor and IL-3-supported myeloid colony formation from normal and leukemic bone marrow cells.
Blood 1990;75(3):633-7.
1990: Bonne Biesma; Elisabeth G E de Vries; P H B Willemse; W J Sluiter; Pieter E Postmus; P C Limburg; A C Stern; Edo Vellenga
Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever.
European journal of cancer (Oxford, England : 1990) 1990;26(9):932-6.
1989: Bouke P C Hazenberg; Miek A van Leeuwen; Martin H van Rijswijk; A C Stern; Edo Vellenga
Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis.
Blood 1989;74(8):2769-70.
1989: J Th M de Wolf; J A Beentjes; Mariet T Esselink; Jan W Smit; R M Halie; S C Clark; Edo Vellenga
In polycythemia vera human interleukin 3 and granulocyte-macrophage colony-stimulating factor enhance erythroid colony growth in the absence of erythropoietin.
Experimental hematology 1989;17(9):981-3.